MedTrace Logo

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01290575 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2012-03-27

No results posted yet for this study

Summary

BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

Placebo

capsule, Oral, 0.0mg, twice daily, 14 day

DRUG

Placebo

Capsule, Oral, 0.0mg, once daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 15mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 60mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, oral, 150mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 300mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 450mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, To be determined (TBD), once daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 5 mg, twice daily, 14 day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290575 on ClinicalTrials.gov